In the competitive arena of weight-loss medicine, Novo Nordisk — once the undisputed architect of the GLP-1 revolution — finds itself in the unfamiliar position of challenger, working to reclaim ground ceded to Eli Lilly through a quiet but determined campaign of delivery innovation. From the first GLP-1 pill to a nascent implant that could reduce dosing to once or twice a year, the Danish company is wagering that how a medicine reaches the body may matter as much as what it does once there. The market has priced Novo Nordisk as an afterthought, but pharmaceutical history is full of underdogs